Expanding the Structural Diversity of DNA Methyltransferase Inhibitors

Area of Science:

• Biochemistry
• Epigenetics
• Drug Discovery

Background:

• DNA methyltransferases (DNMTs) are key targets for epigenetic drug discovery.
• DNMT inhibitors serve as essential chemical tools for studying epigenetic mechanisms.

Purpose of the Study:

• To identify and characterize novel inhibitors of DNA methyltransferase 1 (DNMT1).
• To evaluate the specificity of these inhibitors against DNMT3B.
• To correlate molecular docking predictions with experimental inhibition data.

Main Methods:

• Enzymatic inhibition assays were performed to characterize DNMT1 inhibitors.
• Molecular docking simulations were employed to predict binding interactions.
• The extended connectivity interaction features (eCFP) approach was used for re-scoring docking poses.

Main Results:

• Five distinct DNMT1 inhibitors were identified, with no observed activity against DNMT3B.
• Theaflavin, a dietary compound, was confirmed as a DNMT1 inhibitor.
• Approved drugs glyburide and panobinostat were found to be novel DNMT1 inhibitors.
• Panobinostat's DNMT1 inhibitory activity aligns with previous findings in liver cancer cell lines.
• Molecular docking scores showed excellent agreement with experimental IC50 values.

Conclusions:

• The identified compounds, including theaflavin, glyburide, and panobinostat, are potent and selective DNMT1 inhibitors.
• These inhibitors can advance epigenetic research and therapeutic strategies.
• Computational methods accurately predict the inhibitory potential of small molecules against DNMT1.